Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 1;28(4):276-281.
doi: 10.5737/23688076284276281. eCollection 2018 Fall.

Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs

Sabrina Fowlkes  1 , Cindy Murray  2 , Adrienne Fulford  3 , Tammy De Gelder  4 , Nancy Siddiq  5
Affiliations

Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs

Sabrina Fowlkes et al. Can Oncol Nurs J. .

Abstract

Myeloproliferative neoplasms (MPNs) are rare, yet potentially life-threatening, disorders caused by overproliferation of bone marrow stem cells. The symptom burden experienced by patients with the BCR-ABL1-negative MPNs (also referred to as the classical MPNs, i.e., essential thrombocythemia [ET], polycythemia vera [PV] and myelofibrosis [MF]) can be significant and can negatively impact quality of life (QOL). Since patients with these MPNs can live for several years, thereby requiring long-term treatment and follow-up, nurses play an essential role in communicating with these patients, assessing their symptoms, and educating them on treatments and self-management strategies that can reduce their symptom burden. This article, which is the second of a twopart series, was developed to provide nurses and other healthcare professionals with practical guidance for managing the symptom burden associated with the classical MPNs in order to help enhance their patients' overall health and QOL.

Keywords: essential thrombocythemia; myelofibrosis; myeloproliferative neoplasms; nursing management; polycythemia vera; symptom burden.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST Sabrina Fowlkes has received honoraria from Novartis for speaking engagements, education program development and as a nurse consultant. Cindy Murray has received honoraria from Novartis for educational purposes. Adrienne Fulford has received honoraria from Novartis for speaking and a consultancy meeting. Tammy DeGelder has received honoraria from Novartis for speaking, education and consultancy. Nancy Siddiq has received honoraria from Novartis for educational activities. None of the authors received remuneration for writing of this article.

Figures

Figure 1
Figure 1
The MPN-10
See this image and copyright information in PMC

References

    1. BC Cancer Agency. Nutritional Guidelines for Symptom Management: Early Satiety. 2005. Available online at http://www.bccancer.bc.ca/nutrition-site/Documents/Symptom%20management%....
    1. Centers for Disease Control and Prevention. Chronic Fatigue Syndrome. 2013. Available at: https://www.cdc.gov/cfs/management/treating-symptoms.html.
    1. Cervantes F. How I treat splenomegaly in myelofibrosis. Blood Cancer Journal. 2011;1(10):e37. - PMC - PubMed
    1. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology. 2012;30(33):4098–4103. - PMC - PubMed
    1. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators of Inflammation. 2015;2015:284706. - PMC - PubMed

LinkOut - more resources